Advertisement
Advertisement
MCRB
Seres Therapeutics, Inc.
5.11
USDSponsored
+0.16
+3.23%
Aug 28, 16:00 UTC -4
Closed
After-Market
4.88
-0.24
-4.60%
MCRB Earnings Reports
Positive Surprise Ratio
MCRB beat 21 of 43 last estimates.
49%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$6.48M
/-$1.02
Implied change from Q2 26 (Revenue/ EPS)
+780.03%
/-32.00%
Implied change from Q3 25 (Revenue/ EPS)
+1745.30%
/-208.51%
Seres Therapeutics, Inc. earnings per share and revenue
On Aug 05, 2026, MCRB reported earnings of -1.50 USD per share (EPS) for Q2 26, beating the estimate of -2.22 USD, resulting in a 32.70% surprise. Revenue reached 736.00 thousand, compared to an expected 182.58 thousand, with a 303.11% difference. The market reacted with a -4.67% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -1.02 USD, with revenue projected to reach 6.48 million USD, implying an decrease of -32.00% EPS, and increase of 780.03% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Chemomab Therapeutics Ltd. - ADR
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.24
Surprise
-56.86%
EVOGENE LTD.
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.14
Surprise
+49.16%
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Immatics N.V. Ordinary Shares
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.46
Surprise
-5.70%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-Surprise
-
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-Actual
-$0.35
Surprise
-
FAQ
What were Seres Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Seres Therapeutics, Inc. reported EPS of -$1.50, beating estimates by 32.7%, and revenue of $736.00K, 303.11% above expectations.
How did the market react to Seres Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved down -4.67%, changed from $5.25 before the earnings release to $5.00 the day after.
When is Seres Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Seres Therapeutics, Inc.'s next earnings report?
Based on 3
analysts, Seres Therapeutics, Inc. is expected to report EPS of -$1.02 and revenue of $6.48M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement